Cerulean Announces Data Presentations at the 2016 American Association for …

Cerulean Announces Data Presentations at the 2016 American Association for …

“Two key highlights from the preclinical posters are that combining CRLX101 with either indoleamine 2,3-dioxygenase, or IDO, inhibitors or DNA damage response inhibitors greatly improves antitumor activity as compared to monotherapy. We therefore plan …

(Visited 1 times, 1 visits today)
9
Like
Save

Comments

Comments are disabled for this post.